logo-loader
viewSeelos Therapeutics

Seelos Therapeutics acquires gene therapy program license to treat Parkinson's Disease

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr. Raj Mehra tells Proactive Investors the clinical-stage biopharma has acquired the exclusive worldwide licensing of a gene therapy program from Duke University.

Seelos head of R&D Dr. Tim Whitaker and Dr. Jeffrey Kordower of Rush University Medical Center are working together to move the program forward.

Quick facts: Seelos Therapeutics

Price: 1.07 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $28.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read